Propanc Biopharma, Inc.

Clinical/early-stage biotech — micro clinical-stage, deep losses.

Strengths

• Liquidity — current ratio 1.5 (18th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Exec changeRecent 8-K item 5.02 8-K ↗
• Buying back stockNet buyback — share count -86%/yr over 2y